In recent years, a large number of studies have shown that RNA modifications (acetylation, m6A) affect the progression and prognosis of bladder cancer.[59–62] For example, NAT10 is closely related to the tumorigenicity of bladder cancer, and its overexpression mediates the acetylation modification of mRNA, such as BCL9L, SOX4, and AKT1, in patients with BLCA, thus affecting the progression of bladder cancer.[59] High expression of YTHDF2 is a risk factor for poor prognosis of patients with BLCA. The gene discussed is AKT1; the disease is bladder transitional cell carcinoma.